Key Takeaways
- ASTS shares rose approximately 11% Thursday following the company’s announcement of three additional BlueBird satellite launches scheduled for August via SpaceX’s Falcon 9 rocket.
- The updated deployment timeline positions AST for launches every two months, translating to as many as 18 satellites annually.
- AST has 24 satellites currently in production (BlueBirds 14–37), targeting orbital deployment completion by late 2027.
- Institutional ownership accounts for roughly 61% of shares; company insiders have divested more than $280 million in stock over the past three months.
- Wall Street analysts maintain an average “Reduce” recommendation on ASTS with a consensus target price of $85.09; shares opened Monday at $71.57.
AST SpaceMobile (ASTS) shares advanced approximately 11% Thursday, closing at $71.58, though no immediate news broke that day — the rally followed the company’s recent announcement of an accelerated satellite deployment schedule that has energized market participants.
Earlier this week, AST disclosed that its upcoming trio of BlueBird satellites — designated 11, 12, and 13 — are set for an August liftoff using SpaceX’s Falcon 9 launch vehicle. This deployment comes on the heels of the successful June 17 launch of BlueBirds 8, 9, and 10.
The consecutive launch schedule establishes a rhythm of approximately one launch per two-month period, equating to a possible yearly deployment rate of 18 satellites.
AST is currently manufacturing 24 satellites — BlueBirds 14 through 37. Maintaining the present deployment velocity, the organization anticipates these units will achieve orbit by 2027’s conclusion, coinciding with the planned initiation of beta testing for its direct-to-cellular (DTC) network.
An international component also exists. Statements related to a Vodafone-supported deployment highlighted Spain as a prospective early commercial territory, with a potential 2027 service launch — strengthening the global revenue narrative.
Wall Street Ratings and Target Prices
Despite investor optimism reflected in the stock price, professional analysts maintain a measured to skeptical outlook. The consensus analyst recommendation for ASTS stands at “Reduce,” with an average price objective of $85.09.
Deutsche Bank recently downgraded its position from buy to hold while reducing its price target from $117 to $106. B. Riley shifted to “neutral” with an $85 projection. Roth MKM represents one of the more optimistic perspectives, maintaining a “buy” rating alongside a $108 target.
Among ten analysts monitored, just one maintains a buy recommendation. Six advise holding. Three recommend selling.
The stock’s 50-day moving average currently sits at $87.18, while its 200-day average registers at $89.23 — both significantly exceeding present trading levels.
Heavy Insider Selling Activity
One development that demands attention: corporate insiders have been aggressively reducing their positions.
During the previous 90 days, insiders disposed of more than 3.1 million shares valued at approximately $280.6 million. This includes CFO Andrew Martin Johnson, who offloaded 45,809 shares at an average price of $93.81 on June 11, trimming his holdings by 8.34%.
Director Julio A. Torres similarly divested 15,000 shares at $76.34 in May, decreasing his position by approximately 26%.
Insiders currently control 20.89% of outstanding shares, while institutional investors maintain 60.95%.
SG Americas Securities LLC expanded its ASTS position by 18.6% during Q1, acquiring 11,813 additional shares to reach a total of 75,157.
Regarding financial performance, AST’s Q1 results disappointed. The company reported an EPS of -$0.66, falling short of the -$0.23 estimate. Revenue reached $14.73 million versus the projected $39.01 million.
Analysts project full-year EPS of -$1.47. The stock’s 52-week trading range extends from $36.08 to $133.86.
